Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Marketplace

FDA grants breakthrough designation to Beckman Coulter Alzheimer’s test

February 2025—Beckman Coulter Diagnostics announced the FDA has granted breakthrough device designation to the Access p‑Tau217/β-Amyloid 1-42 plasma ratio. The blood test measures the ratio of phosphorylated tau protein (pTau217) to beta‑amyloid 1-42, two key biomarkers implicated in the neurodegenerative processes of Alzheimer’s disease. A blood-based IVD test that can quantify these biomarkers in plasma could provide a noninvasive, accessible, and earlier method of detecting Alzheimer’s-related pathology, potentially before clinical symptoms manifest, the company said in a statement.

Illumina updates NovaSeq X series

February 2025—Illumina announced a series of updates to its NovaSeq X series, including the NovaSeq X single-flow-cell system, a software upgrade, and new kits.

ARUP launches assay for influenza A (H5) virus

February 2025—ARUP Laboratories has launched an assay for the detection and subtyping of influenza A (H5) virus. The test will aid in the evaluation of people who may have been exposed to highly pathogenic avian influenza (HPAI) A virus, also known as H5N1 or bird flu.

OGT launches NGS SureSeq Myeloid MRD panel

February 2025—OGT announced the North American launch of its next-generation sequencing SureSeq Myeloid MRD panel. The ultra-sensitive panel enables the detection of 13 key measurable residual disease–associated biomarkers in acute myeloid leukemia. Ultralow variant detection, including for very large FLT3-ITDs, enables a stronger characterization of a sample’s current AML status. The company’s complimentary NGS analysis software, Interpret, is available on the cloud or as a local install and provides a powerful bioinformatic analysis pipeline.

Qiagen EZ2 Connect reaches milestone of more than 1,000 placements

February 2025—Qiagen announced it has reached a milestone of having more than 1,000 placements of the EZ2 Connect automated sample preparation instrument. Launched in 2021, the EZ2 Connect is designed to automate the entire process of nucleic acid purification, reducing hands-on time and increasing throughput while maintaining high precision and reproducibility. The company says the system is particularly beneficial for laboratories handling medium volumes of samples for use across a range of downstream molecular biology research applications, such as digital PCR and next-generation sequencing.

BioMérieux acquires immunoassay start-up SpinChip

February 2025—BioMérieux has entered into an agreement to acquire SpinChip Diagnostics (Oslo, Norway), a privately held company that has developed an immunoassay diagnostics platform that can deliver results from a whole blood sample within 10 minutes. SpinChip is initially developing lab-quality tests to address indications common in acute care settings, such as myocardial infarction, and will first focus on high-sensitive troponin I, NT-proBNP, and D-dimer.

Qiagen launches QIAcuityDx dPCR system

January 2025—Qiagen announced the launch of the QIAcuityDx digital PCR system, an IVD medical device that integrates partitioning, thermocycling, and imaging into a streamlined five-plex workflow. The nanoplate-based workflow disperses a sample into thousands of tiny partitions and then reads reactions simultaneously to quantify signals from DNA and RNA.

Pillar expands commercial partnership with Illumina

January 2025—Pillar Biosciences announced an expansion of its existing partnership with Illumina in which a broader portfolio of its OncoReveal NGS panels will be offered directly through Illumina. The additional research use only NGS panels include OncoReveal Core LBx, Essential LBx, and Fusion LBx for liquid biopsy tumor profiling and OncoReveal Multicancer RNA Fusion (18-driver gene RNA panel) and Solid Tumor v2 (48-gene DNA panel) for solid tumor profiling, for use on Illumina’s MiSeq and NextSeq 550 systems.

StatLab launches KT brand slides, cover glass

January 2025—StatLab Medical Products has launched a self-manufactured premium slide and cover glass brand. StatLab KT slides are developed, manufactured, and sold within the StatLab group and include a nonadhesive KT1, standard adhesive KT3+, and advanced adhesive KT5+. KT portfolio slides are validated for use on the company’s PiSmart slide printers and can be used in digital pathology. KT Koverglass, made from Schott D 263M glass, offers high refractive indices and uniform dimensions, resulting in true-to-life color representation and superior clarity, the company says.

MARKETPLACE

TRENDING